Adherence of PARP inhibitor for frontline maintenance therapy in primary epithelial ovarian cancer: a cross-sectional survey

• Published in: Journal of gynecologic oncology Vol. 35; no. 1; pp. e3 - 12
• Main Authors: Kim, Ji Hyun, Lee, Yumi, Kim, Da-Young, Kim, Sinae, Seo, Sang-Soo, Kang, Sokbom, Park, Sang-Yoon, Lim, Myong Cheol
• Format: Journal Article
• Language: English
• Published: Korea (South) Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology; Japan Society of Gynecologic Oncology 01.01.2024; 대한부인종양학회
• Subjects: Antineoplastic Agents - therapeutic use; Carcinoma, Ovarian Epithelial - drug therapy; Cross-Sectional Studies; Female; Humans; Original; Ovarian Neoplasms - drug therapy; Poly(ADP-ribose) Polymerase Inhibitors - pharmacology; Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use; Quality of Life; 산부인과학; Ovarian Cancer; PARP Inhibitor; Survey; Compliance
• ISSN: 2005-0380; 2005-0399; 2005-0399
• DOI: 10.3802/jgo.2024.35.e3

To identify the adherence rate to poly (ADP-ribose) polymerase (PARP) inhibitors and identify factors contributing to the deterioration of adherence at our institution. The adherence rate to PARP inhibitors was calculated using self-reported Adherence to Refills and Medications Scale questionnaires from a cross-sectional survey. Multivariable logistic regression analysis was performed to identify the factors that affected adherence. Of the 131 respondents, 32 (24.4%) showed non-adherence to PARP inhibitors. In the multivariable logistic regression analysis, unemployed or retired status (odds ratio [OR]=4.878; 95% confidence interval [CI]=1.528-15.572; p=0.008), patients receiving niraparib (OR=3.387; 95% CI=1.283-8.940; p=0.014), and a lower score on the quality-of-life assessment (EORTC-QLQ-OV28), which reflects a better quality of life (QOC) with a lower symptom burden (OR=1.056; 95% CI=1.027-1.086; p<0.001) were associated with high adherence to PARP inhibitors. Approximately one-fourth of patients with ovarian cancer are non-adherent to PARP inhibitors as maintenance treatment for newly diagnosed advanced ovarian cancer. The occupational status, type of PARP inhibitor, and QOC may affect adherence to PARP inhibitors.